Last reviewed · How we verify

Cytotec — Competitive Intelligence Brief

Cytotec (Misoprostol) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID combined with prostaglandin analog. Area: Immunology.

marketed NSAID combined with prostaglandin analog Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Cytotec (Misoprostol) — Pfizer. Diclofenac inhibits COX-1/COX-2 to reduce prostaglandins; misoprostol is PGE1 analog protecting gastric mucosa.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Cytotec TARGET Misoprostol Pfizer marketed NSAID combined with prostaglandin analog Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors 1988-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID combined with prostaglandin analog class)

  1. Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cytotec — Competitive Intelligence Brief. https://druglandscape.com/ci/cytotec. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: